Affluent Medical signs agreements with Edwards Lifesciences for mitral valve technologies

Affluent Medical signed several agreements with Edwards Lifesciences on July 12, 2024, for its mitral valve technologies, including an exclusive option to acquire Kephalios, a license for biomimetic cardiac mitral valve replacement technology, and an equity stake, with EUR 15 million upfront payment.

“Affluent Medical signs agreements for mitral valve technologies with EUR 15M upfront payment.”live.euronext.com

• 2 sources
• live.euronext.comAffluent Medical signs agreements for mitral valve technologies with EUR 15M upfront payment.Jul 12, 2024
• massdevice.comAffluent Medical signs $15M mitral valve deals with EdwardsSean WhooleyJul 12, 2024

Summarized from public sources; check the original articles before acting on it.